Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
More News
CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up
The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).
Stocktwits
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
Zacks
Vertex Announces US FDA Approval for Expanded Use of CASGEVY for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive...
Business Wire
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...
Nasdaq News: Markets
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
IBM, Verizon, Corning And A Health Care Stock On CNBC's 'Final Trades'
Jim Lebenthal recommends Vertex Pharmaceuticals in the healthcare sector. Jenny Van Leeuwen picks Verizon, IBM is down 18%, Joseph Terranova chooses Corning.read more...
Benzinga
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals has a marketread more...
Benzinga
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsCRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position...
Nasdaq News: Markets
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the preceding trading day.